the report was compiled by outside researchers who went into the fda�s own database of �serious adverse [medical-drug] events.�
.
.
.
connect with us
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.. a little under 60% of these encounters resulted in hospitalization and of these, about 13% required intensive care.
.
.